Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Grant of Options

26th Mar 2025 07:00

RNS Number : 1500C
Creo Medical Group PLC
26 March 2025
 

Creo Medical Group plc

("Creo", the "Company" or the "Group")

 

Grant of Options

 

Creo Medical Group plc (AIM: CREO), a medical device company focused on the emerging field of minimally invasive surgical endoscopy for pre-cancer and cancer patients, announces that on 24 March 2025, it granted options over an aggregate 6,474,713 ordinary shares of £0.001 in the Company (the "Options") to certain Directors of the Company as follows:

 

Name of Director

Share Options Granted

Exercise Price

Total no. of options over ordinary shares now held

 

Craig Gulliford

2,062,500

£0.13125

9,970,001

Christopher Hancock

1,384,063

£0.13125

7,832,637

Richard Rees

1,410,938

£0.13125

6,066,870

David Woods

1,617,212

£0.13125

3,712,322

 

Vesting of the options is subject to performance conditions through to December 2027.

 

For further information please contact: 

 

Creo Medical Group plc

www.creomedical.com

Richard Craven, Company Secretary

Via Walbrook PR

Deutsche Numis (Nominated Adviser, sole Broker and Financial Adviser)

Freddie Barnfield / Duncan Monteith / Euan Brown / Sher Shah

+44 (0)20 7260 1000

 

Walbrook PR Ltd

Tel: +44 (0)20 7933 8780 or [email protected]

Paul McManus / Alice Woodings

Phillip Marriage

Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654

Mob: +44 (0)7867 984 082

 

 

About Creo Medical

Creo is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy.

 

The Company's vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA powered by Kamaptive full-spectrum adaptive technology to optimise surgical capability and patient outcomes. Kamaptive is a seamless, intuitive integration of multi-modal energy sources, optimised to dynamically adapt to patient tissue during procedures such as resection, dissection, coagulation, and ablation of tissue. Kamaptive technology provides clinicians with increased flexibility, precision and controlled surgical solutions. CROMA currently delivers bipolar radiofrequency ("RF") energy for precise localised cutting and focused high frequency microwave ("MW") energy for controlled coagulation and ablation via a single accessory port. This technology, combined with the Group's range of patented electrosurgical devices, is designed to provide clinicians with flexible, accurate and controlled clinical solutions. The Directors believe the Company's technology can impact the landscape of surgery and endoscopy by providing a safer, less invasive and more cost-efficient option for procedures.

 

For more information, please refer to the website www.creomedical.com

 

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them:

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 

Craig Gulliford

2

 

Reason for the notification

 

a)

 

Position/status

 

 

Chief Executive Officer

b)

 

Initial notification /Amendment

 

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

 

Creo Medical Group plc

b)

 

LEI

 

 

213800H188ZDCWWXFA21

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

 

Description of the financial instrument, type of instrument

Ordinary shares of £0.001 each

Identification code

GB00BZ1BLL44

b)

 

Nature of the transaction

 

 

Grant of Options

c)

 

Price(s) and volume(s)

Price(s)

Volume(s)

Nil

2,062,500

d)

 

Aggregated information

- Aggregated volume

N/A - single transaction

- Price

e)

 

Date of the transaction

 

 

24 March 2025

f)

 

Place of the transaction

 

 

Off-market

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 

Chris Hancock

2

 

Reason for the notification

 

a)

 

Position/status

 

 

Chief Technology Officer

b)

 

Initial notification /Amendment

 

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

 

Creo Medical Group plc

b)

 

LEI

 

 

213800H188ZDCWWXFA21

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

 

Description of the financial instrument, type of instrument

Ordinary shares of £0.001 each

Identification code

GB00BZ1BLL44

b)

 

Nature of the transaction

 

 

Grant of Options

c)

Price(s) and volume(s)

 

 

 

Price(s)

Volume(s)

Nil

1,384,063

 

 

d)

 

Aggregated information

- Aggregated volume

N/A - single transaction

e)

 

Date of the transaction

 

 

24 March 2025

f)

 

Place of the transaction

 

 

Off-market

 

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 

Richard Rees

2

 

Reason for the notification

 

a)

 

Position/status

 

 

Chief Financial Officer

b)

 

Initial notification /Amendment

 

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

 

Creo Medical Group plc

b)

 

LEI

 

 

213800H188ZDCWWXFA21

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

 

Description of the financial instrument, type of instrument

Ordinary shares of £0.001 each

Identification code

GB00BZ1BLL44

b)

 

Nature of the transaction

 

 

Grant of Options

c)

Price(s) and volume(s)

 

 

 

Price(s)

Volume(s)

Nil

1,410,938

 

 

d)

 

Aggregated information

- Aggregated volume

N/A - single transaction

e)

 

Date of the transaction

 

 

24 March 2025

f)

 

Place of the transaction

 

 

Off-market

 

 

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 

David Woods

2

 

Reason for the notification

 

a)

 

Position/status

 

 

Chief Commercial Officer

b)

 

Initial notification /Amendment

 

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

 

Creo Medical Group plc

b)

 

LEI

 

 

213800H188ZDCWWXFA21

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

 

a)

 

Description of the financial instrument, type of instrument

Ordinary shares of £0.001 each

Identification code

GB00BZ1BLL44

b)

 

Nature of the transaction

 

 

Grant of Options

c)

Price(s) and volume(s)

 

 

 

Price(s)

Volume(s)

Nil

1,617,212

 

 

d)

 

Aggregated information

- Aggregated volume

N/A - single transaction

e)

 

Date of the transaction

 

 

24 March 2025

f)

 

Place of the transaction

 

 

Off market

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHFFFFFVRIEFIE

Related Shares:

Creo Medical
FTSE 100 Latest
Value8,658.85
Change-7.27